Abstract 47P
Background
Czech Republic is a center European country with about 10.5 million inhabitants. The aim of analysis was to collect information on epidemiology, treatment and outcomes of sarcoma patients. The Czech National Cancer Registry (CNCR) has been in operation since 1977, when it was instituted as a national database covering 100% of cancer diagnoses and the entire Czech population. The registration of malignant neoplasms is stipulated by the legislation and it is obligatory. The CNCR is a part of the National Health Information System and is administered by the Institute of Health Information and Statistics of the Czech Republic. Out of about 190 hospitals in total is the fully specialized oncology care provided in 15 Complex Oncology Care Centres (COCC).
Methods
There were analyzed data from the CNCR of sarcoma patients diagnosed and treated between 2005-2021. Data of 8 884 soft tissue (STS) and 1 380 bone sarcoma (BS) patients are available. The primary end-point was the overall survival (OS) and the contribution of treatment centralization.
Results
The average incidence in the last 5-year period (2017-2021) was 640 new STS and 87 BS per year (0.85% of all malignancy). The median age was 64 years in STS and 48 years in BS. The incidence has been increasing for the last two decades to 6 per 100 thousand in year. In the last 15 years, the prognosis hasńt changed (except of gastrointestinal stromal sarcoma and BS). 5year OS in STS was 60.1% during 2005-2009, 61.4% during 2010-2015 and 62.6% during 2016-2021, in BS 46.9%, 57.5% and 56.2% respectively. The treatment results depend on early and correct therapy in experiences centres. During 2012-2016, 147 first-contact hospitals and 223 other health centres have participated in the diagnostics and primary treatment. Only 70% of patients were referred to specialized COCC. During 2017-2021 has been a slight reduction in the number of workplaces, but, still 79.5% of patients only were refered to the COCC.
Conclusions
According to the database of CNCR of the Czech Republic, patients have been surgicaly treated in more than 100 various hospitals. One fifth of these patients have never reached specialized treatment in COCC. The centralization of treatment is the only way to improve the prognosis of these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Supported by MH CZ - DRO (MMCI, 00209805) and by Ministry of Health of the Czech Republic grant NV18-07-00073.
Disclosure
All authors have declared no conflicts of interest.